Tomlins Men with Elevated Serum PSA Fusion Transcript Stratifies Prostate Cancer Risk in TMPRSS 2 : ERG Urine
S. Tomlins,S. Aubin,J. Siddiqui,R. Lonigro,Laurie Sefton-Miller,S. Miick,S. Williamsen,Petrea Hodge,J. Meinke,A. Blase,Yvonne Penabella,J. Day,Radhika Varambally,B. Han,D. Wood,L. Wang,M. Sanda,M. Rubin,D. Rhodes,B. Hollenbeck,K. Sakamoto,J. Silberstein,Y. Fradet,J. Amberson,S. Meyers,N. Palanisamy,H. Rittenhouse,John T. Wei,J. Groskopf,A. Chinnaiyan
2011-01-01
Abstract:might also inform the urgency of biopsy after PSA screening. TMPRSS2:ERG+PCA3 different risks of cancer on biopsy; in combination with other clinicopathological features, urine had TMPRSS2:ERG+PCA3 important step in streamlining diagnosis and treatment. Moreover, men with extremes of an −− accurate, individualized stratification of men at high risk for developing clinically significant prostate cancer (in urine), Tomlins and colleagues demonstrated more PCA3 score with levels of PSA (in serum) and TMPRSS2:ERG Who said you can't teach an old gene fusion new tricks? By combining the cancer-specific fusion Prostate Cancer Prevention Trial risk calculator, thus demonstrating clinical utility. improved the performance of the multivariate TMPRSS2:ERG+PCA3 ) in urine. PCA3 ( prostate cancer antigen 3 score with the level of TMPRSS2:ERG clinically significant cancer in patients. Then, the authors combined the score was linked to the presence of cancer, tumor volume, and TMPRSS2:ERG ''score.'' Urine TMPRSS2:ERG this generated a −− developed a clinical-grade, transcription-mediated amplification assay for quantifying fusion mRNA mRNA in urine. First, they TMPRSS2:ERG detected in serum, so the authors decided to test for the presence of overexpressed in more than 50% of PSA-screened prostate cancers. The protein product of this fusion cannot be , is TMPRSS2:ERG ) gene, known as ERG ( v-ets erythroblastosis virus E26 oncogene homolog (avian) gene and the ) TMPRSS2 ( transmembrane protease, serine 2 Recently, it was discovered that the fusion of two genes, the cohorts based on risk for developing the disease. the PSA test by taking a new twist on a known gene fusion, using it to stratify more than 1000 men in two multicenter . improve on et al disease in 2011), it is clear that a more accurate test for prostate cancer is needed. Here, Tomlins Because of the high prevalence of prostate cancer (it is estimated that nearly 250,000 men will be diagnosed with the contribute to high levels of PSA, resulting in a ''false-positive'' and subsequent overdiagnosis and overtreatment. recommended for definitive diagnosis. This test is not perfect; benign conditions, such as an enlarged prostate, can the level of prostate-specific antigen (PSA) in the blood, and if that level is above a predefined cutoff, a biopsy is The ''PSA test'' is a routine test for men over the age of 50 or for those at risk for prostate cancer. It measures Old Gene Fusion, New Diagnostic Tricks